Skip to main content

PIONEER 4: A Study Investigating the Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus

PIONEER 4: A Study Investigating the Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus

Principal Investigator

Sponsor

Novo Nordisk

Before a new medicine can be approved for use in humans, it is necessary to confirm that it is safe and effective. This is done by carrying out studies such as this one. The study product semaglutide is being developed for treatment of type 2 diabetes. The purpose of the study is to compare the effect and safety of semaglutide versus or Victoza, a product already approved for treatment of type 2 diabetes.